M
OBIO icon

Murchinson’s Orchestra BioMed OBIO Stock Holding History

Murchinson’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100,115
Closed -$992K – 114
2022
Q1 		$992K Sell
100,115
-199,885
-67% -$1.97M 0.19% 49
2021
Q4 		$3.02M Hold
300,000
– – 0.29% 31
2021
Q3 		$2.97M Hold
300,000
– – 1.47% 24
2021
Q2 		$3.06M Buy
+300,000
New +$3.1M 1.1% 28

Other funds holding OBIO

D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
CC
Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return

Murchinson's OBIO Position: Q2 2022 in Review

Murchinson sold out of Orchestra BioMed (OBIO) in Q2 2022, closing a stake of 100,115 shares — an estimated $992K sold.

Murchinson first reported a position in OBIO in Q2 2021 and held it in 4 quarters. The position peaked at $3.06M in Q2 2021. 62 funds tracked by Wall St. Rank hold OBIO as of Q2 2022.

  • Murchinson reported no remaining Orchestra BioMed position as of Q2 2022 after selling out during the quarter.
  • Murchinson sold 100,115 Orchestra BioMed shares in Q2 2022, an estimated $992K.
  • Murchinson first reported a position in Orchestra BioMed in Q2 2021 and held it in 4 quarters.
  • Murchinson's Orchestra BioMed position peaked at $3.06M in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2022.

Based on Murchinson's 13F filing for Q2 2022, filed 15 Aug 2022.